Research
Hormonal
Fasting Mimicking Diets (FMD) and Intermittent Fasting (IF) offer metabolic benefits similar to continuous calorie restriction but with better compliance and potential protective effects against chemotherapy side effects, though long-term weight loss efficacy is modest.
If you struggle with daily calorie counting, try Intermittent Fasting or Fasting Mimicking Diets. They can improve metabolic markers and may protect you during cancer treatment. However, don't expect massive long-term weight loss from IF alone; it's a tool for metabolic health and compliance, not a magic bullet.
ModerateQualifiesMEDIUM confidence
Intermittent fasting... allows an average weight loss of 4–10% in periods of 4–24 weeks... in the few studies lasting >6 months the reported results they are modest... fasting can activate a sustained evolutionary molecular response to metabolic stress in normal cells, inhibiting their proliferation, increasing the maintenance of self with effect of protection from chemotherapy.
Why this rating
Narrative review of preclinical and some clinical studies; long-term human data is limited.
Source
A Clinical Perspective of Low Carbohydrate Ketogenic Diets: A Narrative Review
Samir Giuseppe Sukkar et al. · Frontiers in Nutrition · 2021
DOI 10.3389/fnut.2021.642628
narrative_reviewCited 56×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Very Low-Calorie Ketogenic Diets (VLCKD) and Protein-Sparing Modified Fasting (PSMF) produce rapid, significant weight loss and preserve lean mass in obese patients, but require strict medical supervision due to risks of gallbladder issues and electrolyte imbalance.Moderate
- Hyperlipidic, high-protein low-carb diets (e.g., Atkins, Paleo) are effective for short-term weight loss but are not recommended as long-term healthy lifestyle models due to negative effects on LDL cholesterol and microbiota.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →